



The 27th JFCR-ISCC New Antitumor Agents under Development in the US, Europe and Japan

2023 December 13 (Wed) 12:50 -19:10
December 14 (Thu) 9:00 -16:20

Miraikan

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 13 (Wed)

Session 1 **Targeting RAS/RAF/MAPK Pathway**

13:00 -

Hiromichi Ebi *Aichi Cancer Ctr.*

Genetic and non-genetic mechanisms of resistance to KRAS inhibitors

Zhe Chen *Revolution Medicines, USA*

Targeting the oncogenic state of RAS with TriComplex inhibitors

Masahiko Hayakawa *Astellas Pharma*

KRAS G12D degrader: ASP3082

Ryan Corcoran *MGH, USA*

Harnessing the immune response to BRAF inhibition in BRAF V600E colorectal cancerer

Meet-the-Expert Session

15:30 -

Developing a novel TKI for a rare indication in a crowded market, DO-2 as example

Jaap Verweij *Erasmus Univ., Netherlands*

Session 2 **Special Session**

16:30 -

History and Future of Cancer Chemotherapy

Yves Pommier *NCI, NIH, USA*

Schlafen 11 at the intersection of genomics and proteotoxic stress

Hiroyuki Seimiya *Cancer Chemother. Ctr., JFCR*

Targeting tankyrase-specific PARylation for cancer therapy

Bruce A. Chabner *MGH, USA*

History and future of cancer therapy

18:30 -

Poster Viewing

Dec. 14 (Thu)

Session 3 **Toward Development of Next-generation Cancer Immunotherapies**

9:00 -

Shohei Koyama *EPOC, NCC*

Adaptive and acquired resistance to cancer immunotherapy

Sacha Gnjatic *Icahn School Med. Mount Sinai, USA*

Guiding new immunotherapies with purposefully designed immune monitoring

Ping-Chih Ho *Univ. Lausanne, Switzerland*

Re-directing T cell immune response by tailoring mitochondrial programming

Poster Session

11:00 -

Poster Presentation and Discussion

Luncheon Seminar

12:10 -

Design of cell microenvironments for construction of three-dimensional tissue models

Supported by **TOPPAN**

Michiya Matsusaki *Osaka Univ.*

Session 4 **Cell Therapy and Multifunctional Antibodies**

13:10 -

Naoki Hosen *Osaka Univ.*

Identification of novel target antigens of CAR T cell therapy for hematological cancers

Hirofumi Mikami *Chugai Pharmaceutical*

Next generation T-cell engagers

Session 5 **New Drugs under Clinical or Preclinical Evaluations**

14:20 -

Masanori Okaniwa *Takeda Pharmaceutical*

COnditional Bispecific Redirection Activation (COBRA) T cell engagers: Solid tumor pipeline strategy and ongoing clinical trials

Sosuke Nakamura *MSD*

Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289, MK-3543) for the Treatment of Essential Thrombocythemia (ET)

Paul Workman *Inst. Cancer Res., UK*

NXP800: a first-in-class, orally available, clinical-stage, investigational activator of the integrated stress response for treatment of ARID1A-mutated, platinum-resistant ovarian cancer

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfc-r.or.jp

<http://iscc.umin.jp/>

The 27th JFCR-ISCC is supported by following companies:MSD K.K., Kyowa Kirin Co., Ltd., Amgen K.K., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd, Ono Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd.